Silvia de Sanjose Llongueras
Dr. Silvia de Sanjosé holds a Medical degree (University of Barcelona-UB, 1980), Specialty in Family practice and Community Medicine (University of Barcelona-UB,1983), and a MSc in Epidemiology (London School of Hygiene and Tropical Medicine-LSHTM, University of London-UCL, 1986). She got her Philosophy Doctor degree in 1989 (London School of Hygiene and Tropical University-LSHTM, University of London-UCL, 1989) and the Doctoral Degree from the University of Barcelona.
She trained at the General Hospital of Alicante, Spain (1981-82) and at the Primary Health Centre of Cornella, Spain (1983). She work as Research fellow in the Institut Municipal de Salut Pública of Barcelona, Spain (1984-85), in the Department of Epidemiology of the London School of Hygiene and Tropical Medicine, London, UK (1988) , at the Unit of Field and Intervention Studies of the International Agency for Research on Cancer (IARC), Lyon, France (1989-1993), a sabbatical period in 2002-03 at the National Institute of Cancer in the US, and a sabbatical period at CREAL in 2014, Barcelona.
She has nearly 30 years of expertise in epidemiology of HPV and related cancers, including her participation in the first studies showing the causal association of HPV with cancer, such as the IARC multi-centric case-control study on invasive cervical cancer, the IARC multi-centric prevalence study. She joined the Cancer Epidemiology Research Program (PREC) at the Catalan Institute of Oncology (ICO) in 1993, first as Senior Epidemiologist and later as Head of the Program. While at PREC, she worked on large international studies involving HPV worldwide genotyping (RIS HPV TT, VVAP) that involve the collaboration of more than 50 countries. At PREC she also worked on HPV based screening guidelines for cervical cancer in Catalonia and Spain and has I been involved in research projects exploring the relationship between HIV and HPV.
Now she is a senior consultant at PATH (for which she was previously Director of the Women’Cancer program), at NCI (as senior consultant at the Accelerated Cervical Cancer Control: Cancer Moonshot) and at PREC. Moreover, she is the President of the Multidisciplinary Collaborative Group for the Scientific Monitoring of COVID-19.
She served as the President of the International Papillomavirus Society during 2015-2018 and has been Co-Chair of the Cape Town, Sydney and Virtual-Barcelona conferences of the IPVS. She is also an affiliated professor at the Department of Epidemiology, University of Washington.
de Sanjose S, Holme F. What is needed now for successful scale-up of screening? Papillomavirus Res. 2019 Jun;7:173-175. doi: 10.1016/j.pvr.2019.04.011
Thomson KA, Sandoval M, Bain C, (…) de Sanjosé S. Recall Efforts Successfully Increase Follow-Up for Cervical Cancer Screening Among Women With Human Papillomavirus in Honduras. Glob Health Sci Pract. 2020 Jun 30;8(2):290-299. doi: 10.9745/GHSP-D-19-00404
Holme F, Jeronimo J, Maldonado F, (…) de Sanjose S. Introduction of HPV testing for cervical cancer screening in Central America: The Scale-Up project. Prev Med. 2020 Jun;135:106076. doi: 10.1016/j.ypmed.2020.106076
Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016 Dec 1;2:16086. doi: 10.1038/nrdp.2016.86
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8
Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27. doi: 10.1056/NEJMoa021641
de Sanjosé S, Serrano B, Tous S, et al. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2019 Jan 7;2(4):pky045. doi: 10.1093/jncics/pky045
Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018 Jan;5(1):e45-e58. doi: 10.1016/S2352-3018(17)30149-2
de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:2-13. doi: 10.1016/j.bpobgyn.2017.08.015